i am aaron kesselheim to introduce the final panel of the day that relates to another important set of public health functions, that greater transparency about information and regulatory decisions about the fda can play. i want to thank alyou for hosti this, for organizing the publishing of the special supplement, and of course to commissioner gottlieb for his remarks at the beginning of the day. so the focus of this final panel today is the fact that in certain high profile cases, manufacturers have released incorrect or incomplete information into the market. that was directly counter to information that contemporaneous information the fda had. and in the 2010 fda transparency taskforce that he led, they noted selective publication of clinical trial results has in the past created a misleading picture of safety and efficacy of a product with negative implications for public health, and as the practice now still stands, manufacturers have wide latitude to publicly characterize daylight characterize data submitted to the fda without the fda correcting the record. something we'll talk a